These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 7508663)
21. The future of antigen-specific immunotherapy of allergy. Valenta R Nat Rev Immunol; 2002 Jun; 2(6):446-53. PubMed ID: 12093011 [TBL] [Abstract][Full Text] [Related]
22. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy. Möbs C; Slotosch C; Löffler H; Pfutzner W; Hertl M Int Arch Allergy Immunol; 2008; 147(3):171-8. PubMed ID: 18594146 [TBL] [Abstract][Full Text] [Related]
23. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. Vrtala S; Ball T; Spitzauer S; Pandjaitan B; Suphioglu C; Knox B; Sperr WR; Valent P; Kraft D; Valenta R J Immunol; 1998 Jun; 160(12):6137-44. PubMed ID: 9637531 [TBL] [Abstract][Full Text] [Related]
24. Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy. Weghofer M; Grote M; Dall'Antonia Y; Fernández-Caldas E; Krauth MT; van Hage M; Horak F; Thomas WR; Valent P; Keller W; Valenta R; Vrtala S Int Arch Allergy Immunol; 2008; 147(2):101-9. PubMed ID: 18520154 [TBL] [Abstract][Full Text] [Related]
26. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361 [TBL] [Abstract][Full Text] [Related]
27. [The value of immunotherapy in treatment of IgE-induced allergic diseases]. Müller UR Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841 [TBL] [Abstract][Full Text] [Related]
28. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007 [TBL] [Abstract][Full Text] [Related]
29. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. Hiller R; Laffer S; Harwanegg C; Huber M; Schmidt WM; Twardosz A; Barletta B; Becker WM; Blaser K; Breiteneder H; Chapman M; Crameri R; Duchêne M; Ferreira F; Fiebig H; Hoffmann-Sommergruber K; King TP; Kleber-Janke T; Kurup VP; Lehrer SB; Lidholm J; Müller U; Pini C; Reese G; Scheiner O; Scheynius A; Shen HD; Spitzauer S; Suck R; Swoboda I; Thomas W; Tinghino R; Van Hage-Hamsten M; Virtanen T; Kraft D; Müller MW; Valenta R FASEB J; 2002 Mar; 16(3):414-6. PubMed ID: 11790727 [TBL] [Abstract][Full Text] [Related]
30. Impact of native, recombinant, and cross-reactive allergens on humoral and T-cell-mediated immune responses. Crameri R; Rhyner C Immunol Allergy Clin North Am; 2007 Feb; 27(1):65-78. PubMed ID: 17276879 [TBL] [Abstract][Full Text] [Related]
31. [Specific immunotherapy in allergies--evaluation of current status]. Jarisch R; Hemmer W Wien Med Wochenschr; 1996; 146(15):422-5. PubMed ID: 9012204 [TBL] [Abstract][Full Text] [Related]
32. [Diagnostic and therapeutic value of synthetic or recombinant allergens]. Spertini F Rev Med Suisse Romande; 1999 Mar; 119(3):235-9. PubMed ID: 10218421 [TBL] [Abstract][Full Text] [Related]
33. Animal models of type I allergy using recombinant allergens. Herz U; Renz H; Wiedermann U Methods; 2004 Mar; 32(3):271-80. PubMed ID: 14962762 [TBL] [Abstract][Full Text] [Related]